Raqia Therapeutics
Marc A. Cohen is Executive Chairman of Raqia Therapeutics. Marc is also Chief Executive Officer and Co-Founder of Cobro Ventures; Executive Chair and Co-Founder of C4 Therapeutics (Nasdaq: CCCC); Chairman of Frequency Therapeutics (Nasdaq: FREQ); Chief Executive Officer, Executive Chair and Co-Founder of NextRNA Therapeutics; Executive Chairman and Co-Founder of Mana Therapeutics; Executive Chairman and Co-Founder of Regency Pharmaceuticals, Co-Chief Executive Officer and Co-Founder of Bublup Inc.; and Dana-Farber Trustee and Co-Founder of Dana-Farber’s Innovation Fund. In addition, Marc was the Co-Founder, Chief Executive Officer, and Chairman of OPNET Technologies, Inc. (Nasdaq: OPNT), a world leader in network and application performance management. OPNET was sold to Riverbed Technology (Nasdaq: RVBD) in December 2012.
This person is not in the org chart
This person is not in any offices
Raqia Therapeutics
Raqia Therapeutics is an exciting startup company developing a transformative chimeric antigen receptor (CAR) technology for immunotherapy. At Raqia Therapeutics, they are motivated to bring life-changing therapy to patients with cancer.